Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
LISRAYA is the first FDA-approved targeted therapy for dermatomyositis. ELK GROVE VILLAGE, Ill., Aug. 28, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib), a once-daily...